Cempra Inc (CEMP) 22.20 $CEMP
Cempra’s New Drug Holds Potential, but Risk for Investors
at The Street - Fri Oct 30, 8:32AM CDT
The company is seeking approval for a promising antibiotic, but investors may be wary of side effects that occurred during testing.
CEMP: 22.20 (-1.63)
Why Cempra Inc is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 28, 1:18PM CDT
What: Shares of Cempra , a clinical-stage biopharma focused on developing next-generation antibiotics, were up more than 11% today on higher than normal volume. So what: While there doesn't appear to be any specific news that justifies the...
CEMP: 22.20 (-1.63)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 3.70 (unch), IRWD: 11.36 (+0.16), SHPG: 227.05 (+0.53), GSK: 43.06 (+0.27), CEMP: 22.20 (-1.63)
Cempra to Present Solithromycin Oral Data at CHEST 2015
GlobeNewswire - Fri Oct 23, 8:25AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making an oral presentation for solithromycin at CHEST 2015, the annual meeting of the American College of Chest Physicians, being held in Montreal from October 24-28, 2015.
CEMP: 22.20 (-1.63)
Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Review, H2 2015 - 14 Companies & 19 Drug Profiles
M2 - Fri Oct 23, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/smvsbm/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ironwood Pharmaceuticals, Inc. - Johnson & Johnson - RaQualia Pharma Inc. - Shire Plc - Sucampo Pharmaceuticals, Inc. - Vecta Ltd. - Wockhardt Limited - Yuhan Corporation - Yuyu Pharma, Inc. Drug Profiles - ARH-1029 - cobiprostone - DWJ-1367 - E-3710 - esomeprazole magnesium - G-17DT - IW-3718 - JNJ-26070109 - omeprazole - pantoprazole - RQ-00000004 - RQ-00000774 - Small Molecule for Peptic Ulcers - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Small Molecules to Block Proton Pump for Gastrointestinal Disorders - SSP-002358 - tenatoprazole - YH-4808 - YY-DXR For more information visit http://www.researchandmarkets.com/research/smvsbm/reflux
JNJ: 101.03 (-0.34), IRWD: 11.36 (+0.16), SHPG: 227.05 (+0.53), SCMP: 19.36 (+0.25), CEMP: 22.20 (-1.63)
5 High-Risk, High-Reward Stocks We're Watching
Brian Feroldi, Dan Caplinger, Matthew Frankel, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Oct 23, 5:24AM CDT
Image source: Pictures of Money via Flickr Creative Commons. While we Fools tend to fill our portfolios with companies on rock-solid financial footing in dominate competitive positions, we certainly recognize that it can be prudent to invest in...
BLUE: 77.13 (-1.96), BIDU: 187.47 (+18.48), AFH: 19.02 (-0.28), CEMP: 22.20 (-1.63)
Cempra reports 3Q loss
Automated Insights - Thu Oct 22, 6:28AM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Thursday reported a loss of $27.6 million in its third quarter.
CEMP: 22.20 (-1.63)
Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Oct 22, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended September 30, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 8:00 a.m. EDT.
CEMP: 22.20 (-1.63)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 308.47 (+4.09), PFE: 33.82 (-0.95), CEMP: 22.20 (-1.63)
Cempra to Report Third Quarter 2015 Financial Results
GlobeNewswire - Mon Oct 19, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2015 financial results before the open of U.S. financial markets on Thursday, October 22, 2015. Cempra management will host a webcast and conference call at 8:00 a.m. EDT that day to discuss the financial results and provide a corporate update.
CEMP: 22.20 (-1.63)
4 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
at The Street - Fri Oct 16, 1:50PM CDT
These stocks are seeing big trading volume today. Here's how you can trade them.
PWR: 20.11 (+0.26), HAL: 38.38 (+0.19), CEMP: 22.20 (-1.63), GNW: 4.68 (-0.54)
Is Cempra's 33% Drop Warranted?
George Budwell, The Motley Fool - Motley Fool - Fri Oct 16, 10:49AM CDT
What : Shares of Cempra , a clinical-stage biopharma, crashed today following a positive update for the company's late-stage fourth generation macrolide, solithromycin, indicated as a potential treatment for community acquired bacterial pneumonia...
CEMP: 22.20 (-1.63)
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Oct 16, 6:00AM CDT
Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
CEMP: 22.20 (-1.63)
Cempra to Present Solithromycin Data at ID Week 2015
GlobeNewswire - Mon Oct 05, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making two poster presentations at Infectious Disease Week 2015, being held in San Diego from October 7-11, 2015.
CEMP: 22.20 (-1.63)
Technical Insights on the Healthcare Sector -- Aerie Pharmaceuticals, Dyax, Cempra, B/E Aerospace and Capstone Turbine
PR Newswire - Thu Sep 24, 8:06AM CDT
ACI Association has initiated research coverage on the following equities: Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Dyax Corp. (NASDAQ: DYAX), Cempra, Inc. (NASDAQ: CEMP), B/E Aerospace, Inc. (NASDAQ: BEAV), Capstone Turbine Corporation (NASDAQ: CPST). On Wednesday, September 23, 2015, Nasdaq ended at 4752.74, down 0.08%, Dow Jones declined 0.31%, to finish the day at 16279.89, and the S&P closed at 1938.76, down 0.20%. Register for your complimentary reports at the links given below.
CPST: 0.20 (-0.01), BEAV: 46.95 (-0.61), AERI: 22.81 (+0.19), CEMP: 22.20 (-1.63), DYAX: 27.53 (-0.13)
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
GlobeNewswire - Thu Sep 24, 6:29AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making a poster presentation at the European Respiratory Society (ERS) International Congress, being held in Amsterdam from September 26-30, 2015.
CEMP: 22.20 (-1.63)
Stock Futures Turn Nose Down; Adobe, Tata, Global Payments Dive
at Investor's Business Daily - Fri Sep 18, 8:13AM CDT
Stock futures deteriorated from mild to steep losses en route to Friday's open, as global markets continued to gyrate following the Federal Reserve's policy decision on Thursday. Dow futures accelerated their declines to 202.7 points below fair...
F: 14.81 (+0.08), TM: 122.62 (-0.62), FCAU: 14.64 (+0.08), ADBE: 88.66 (+0.54), TTM: 29.57 (-0.01), GS: 187.50 (-2.39), GPN: 136.41 (-0.02), GM: 34.91 (+0.16), CEMP: 22.20 (-1.63), HMC: 33.13 (+0.15), BHI: 52.68 (+0.09)
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
GlobeNewswire - Fri Sep 18, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Cempra's investigational antibiotic product candidate, Taksta(TM) (CEM-102, sodium fusidate, the sodium salt of fusidic acid). The designation is for Taksta oral tablets for the indication of acute bacterial skin and skin structure infections (ABSSSI).
CEMP: 22.20 (-1.63)
Updates on Biotechnology Industry Stocks - BioCryst Pharma, Incyte, bluebird bio, Cempra, and BioLineRx
PR Newswire - Fri Sep 11, 8:30AM CDT
Equity Research Institute has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Incyte Corporation (NASDAQ: INCY), bluebird bio Inc. (NASDAQ: BLUE), Cempra Inc. (NASDAQ: CEMP), and BioLineRx Ltd (NASDAQ: BLRX). Free research report on BioCryst Pharma can be accessed at https://www.erionline.net/reports?keyword=BCRX On Thursday, September 10, 2015, the NASDAQ Composite ended at 4,796.25, up 0.84%, the Dow Jones Industrial Average edged 0.47% higher, to finish the day at 16,330.40, and the S&P 500 closed at 1,952.29, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
BLUE: 77.13 (-1.96), BCRX: 8.99 (-0.43), INCY: 117.53 (+0.50), CEMP: 22.20 (-1.63), BLRX: 1.35 (+0.03)
Cempra to Present Data From Antibiotic Drug Development Programs at ICAAC/ICC 2015 Meeting
GlobeNewswire - Thu Sep 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making multiple presentations on solithromycin and Taksta(TM) (fusidic acid) at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015.
CEMP: 22.20 (-1.63)
Cempra’s New Drug Holds Potential, but Risk for Investors
at The Street - Fri Oct 30, 8:32AM CDT
The company is seeking approval for a promising antibiotic, but investors may be wary of side effects that occurred during testing.
CEMP: 22.20 (-1.63)
Why Cempra Inc is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 28, 1:18PM CDT
What: Shares of Cempra , a clinical-stage biopharma focused on developing next-generation antibiotics, were up more than 11% today on higher than normal volume. So what: While there doesn't appear to be any specific news that justifies the...
CEMP: 22.20 (-1.63)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 3.70 (unch), IRWD: 11.36 (+0.16), SHPG: 227.05 (+0.53), GSK: 43.06 (+0.27), CEMP: 22.20 (-1.63)
Cempra to Present Solithromycin Oral Data at CHEST 2015
GlobeNewswire - Fri Oct 23, 8:25AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making an oral presentation for solithromycin at CHEST 2015, the annual meeting of the American College of Chest Physicians, being held in Montreal from October 24-28, 2015.
CEMP: 22.20 (-1.63)
Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Review, H2 2015 - 14 Companies & 19 Drug Profiles
M2 - Fri Oct 23, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/smvsbm/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ironwood Pharmaceuticals, Inc. - Johnson & Johnson - RaQualia Pharma Inc. - Shire Plc - Sucampo Pharmaceuticals, Inc. - Vecta Ltd. - Wockhardt Limited - Yuhan Corporation - Yuyu Pharma, Inc. Drug Profiles - ARH-1029 - cobiprostone - DWJ-1367 - E-3710 - esomeprazole magnesium - G-17DT - IW-3718 - JNJ-26070109 - omeprazole - pantoprazole - RQ-00000004 - RQ-00000774 - Small Molecule for Peptic Ulcers - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Small Molecules to Block Proton Pump for Gastrointestinal Disorders - SSP-002358 - tenatoprazole - YH-4808 - YY-DXR For more information visit http://www.researchandmarkets.com/research/smvsbm/reflux
JNJ: 101.03 (-0.34), IRWD: 11.36 (+0.16), SHPG: 227.05 (+0.53), SCMP: 19.36 (+0.25), CEMP: 22.20 (-1.63)
5 High-Risk, High-Reward Stocks We're Watching
Brian Feroldi, Dan Caplinger, Matthew Frankel, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Oct 23, 5:24AM CDT
Image source: Pictures of Money via Flickr Creative Commons. While we Fools tend to fill our portfolios with companies on rock-solid financial footing in dominate competitive positions, we certainly recognize that it can be prudent to invest in...
BLUE: 77.13 (-1.96), BIDU: 187.47 (+18.48), AFH: 19.02 (-0.28), CEMP: 22.20 (-1.63)
Cempra reports 3Q loss
Automated Insights - Thu Oct 22, 6:28AM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Thursday reported a loss of $27.6 million in its third quarter.
CEMP: 22.20 (-1.63)
Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Oct 22, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended September 30, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 8:00 a.m. EDT.
CEMP: 22.20 (-1.63)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 308.47 (+4.09), PFE: 33.82 (-0.95), CEMP: 22.20 (-1.63)
Cempra to Report Third Quarter 2015 Financial Results
GlobeNewswire - Mon Oct 19, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2015 financial results before the open of U.S. financial markets on Thursday, October 22, 2015. Cempra management will host a webcast and conference call at 8:00 a.m. EDT that day to discuss the financial results and provide a corporate update.
CEMP: 22.20 (-1.63)
4 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
at The Street - Fri Oct 16, 1:50PM CDT
These stocks are seeing big trading volume today. Here's how you can trade them.
PWR: 20.11 (+0.26), HAL: 38.38 (+0.19), CEMP: 22.20 (-1.63), GNW: 4.68 (-0.54)
Is Cempra's 33% Drop Warranted?
George Budwell, The Motley Fool - Motley Fool - Fri Oct 16, 10:49AM CDT
What : Shares of Cempra , a clinical-stage biopharma, crashed today following a positive update for the company's late-stage fourth generation macrolide, solithromycin, indicated as a potential treatment for community acquired bacterial pneumonia...
CEMP: 22.20 (-1.63)
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Oct 16, 6:00AM CDT
Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
CEMP: 22.20 (-1.63)
Cempra to Present Solithromycin Data at ID Week 2015
GlobeNewswire - Mon Oct 05, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making two poster presentations at Infectious Disease Week 2015, being held in San Diego from October 7-11, 2015.
CEMP: 22.20 (-1.63)
Technical Insights on the Healthcare Sector -- Aerie Pharmaceuticals, Dyax, Cempra, B/E Aerospace and Capstone Turbine
PR Newswire - Thu Sep 24, 8:06AM CDT
ACI Association has initiated research coverage on the following equities: Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Dyax Corp. (NASDAQ: DYAX), Cempra, Inc. (NASDAQ: CEMP), B/E Aerospace, Inc. (NASDAQ: BEAV), Capstone Turbine Corporation (NASDAQ: CPST). On Wednesday, September 23, 2015, Nasdaq ended at 4752.74, down 0.08%, Dow Jones declined 0.31%, to finish the day at 16279.89, and the S&P closed at 1938.76, down 0.20%. Register for your complimentary reports at the links given below.
CPST: 0.20 (-0.01), BEAV: 46.95 (-0.61), AERI: 22.81 (+0.19), CEMP: 22.20 (-1.63), DYAX: 27.53 (-0.13)
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
GlobeNewswire - Thu Sep 24, 6:29AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making a poster presentation at the European Respiratory Society (ERS) International Congress, being held in Amsterdam from September 26-30, 2015.
CEMP: 22.20 (-1.63)
Stock Futures Turn Nose Down; Adobe, Tata, Global Payments Dive
at Investor's Business Daily - Fri Sep 18, 8:13AM CDT
Stock futures deteriorated from mild to steep losses en route to Friday's open, as global markets continued to gyrate following the Federal Reserve's policy decision on Thursday. Dow futures accelerated their declines to 202.7 points below fair...
F: 14.81 (+0.08), TM: 122.62 (-0.62), FCAU: 14.64 (+0.08), ADBE: 88.66 (+0.54), TTM: 29.57 (-0.01), GS: 187.50 (-2.39), GPN: 136.41 (-0.02), GM: 34.91 (+0.16), CEMP: 22.20 (-1.63), HMC: 33.13 (+0.15), BHI: 52.68 (+0.09)
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
GlobeNewswire - Fri Sep 18, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Cempra's investigational antibiotic product candidate, Taksta(TM) (CEM-102, sodium fusidate, the sodium salt of fusidic acid). The designation is for Taksta oral tablets for the indication of acute bacterial skin and skin structure infections (ABSSSI).
CEMP: 22.20 (-1.63)
Updates on Biotechnology Industry Stocks - BioCryst Pharma, Incyte, bluebird bio, Cempra, and BioLineRx
PR Newswire - Fri Sep 11, 8:30AM CDT
Equity Research Institute has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Incyte Corporation (NASDAQ: INCY), bluebird bio Inc. (NASDAQ: BLUE), Cempra Inc. (NASDAQ: CEMP), and BioLineRx Ltd (NASDAQ: BLRX). Free research report on BioCryst Pharma can be accessed at https://www.erionline.net/reports?keyword=BCRX On Thursday, September 10, 2015, the NASDAQ Composite ended at 4,796.25, up 0.84%, the Dow Jones Industrial Average edged 0.47% higher, to finish the day at 16,330.40, and the S&P 500 closed at 1,952.29, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
BLUE: 77.13 (-1.96), BCRX: 8.99 (-0.43), INCY: 117.53 (+0.50), CEMP: 22.20 (-1.63), BLRX: 1.35 (+0.03)
Cempra to Present Data From Antibiotic Drug Development Programs at ICAAC/ICC 2015 Meeting
GlobeNewswire - Thu Sep 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making multiple presentations on solithromycin and Taksta(TM) (fusidic acid) at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015.
CEMP: 22.20 (-1.63)
